Literature DB >> 23912821

Ifosfamide induced renal rickets.

Arul P Lionel1, Girish Chinnaswamy, Rikki R John, Sarah Mathai.   

Abstract

Ifosfamide is commonly used as a chemotherapeutic agent in children. The authors report a 4-y-old boy who developed proximal renal tubulopathy with florid rickets a year after completion of ifosfamide therapy for Ewing's sarcoma. After initiation of treatment, there was complete healing of rickets and he did not need supplements beyond 18 mo. Growth monitoring and musculoskeletal system examination is important in all children who have received ifosfamide therapy. Routine monitoring for nephrotoxicity during and after ifosfamide therapy helps in early identification and intervention.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23912821     DOI: 10.1007/s12098-013-1112-x

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  9 in total

1.  Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the Late Effects Surveillance System.

Authors:  W Stöhr; M Paulides; S Bielack; H Jürgens; J Treuner; R Rossi; T Langer; J D Beck
Journal:  Pediatr Blood Cancer       Date:  2007-04       Impact factor: 3.167

2.  Ifosfamide metabolite chloroacetaldehyde causes renal dysfunction in vivo.

Authors:  J E Springate
Journal:  J Appl Toxicol       Date:  1997 Jan-Feb       Impact factor: 3.446

3.  Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation.

Authors:  Jeannine S McCune; Linda J Risler; Brian R Phillips; Kenneth E Thummel; David Blough; Danny D Shen
Journal:  Drug Metab Dispos       Date:  2005-04-08       Impact factor: 3.922

4.  Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dose.

Authors:  Roderick Skinner; Annie Parry; Lisa Price; Michael Cole; Alan W Craft; Andrew D J Pearson
Journal:  Pediatr Blood Cancer       Date:  2010-07-01       Impact factor: 3.167

5.  Development of ifosfamide-induced nephrotoxicity: prospective follow-up in 75 patients.

Authors:  R Rossi; J Pleyer; P Schäfers; N Kuhn; R Kleta; T Deufel; H Jürgens
Journal:  Med Pediatr Oncol       Date:  1999-03

Review 6.  Chronic ifosfamide nephrotoxicity in children.

Authors:  R Skinner
Journal:  Med Pediatr Oncol       Date:  2003-09

7.  Long-term evaluation of Ifosfamide-related nephrotoxicity in children.

Authors:  Odile Oberlin; Oumaya Fawaz; Annie Rey; Patrick Niaudet; Vita Ridola; Daniel Orbach; Christophe Bergeron; Annie Sophie Defachelles; Jean-Claude Gentet; Claudine Schmitt; Hervé Rubie; Martine Munzer; Dominique Plantaz; Anne Deville; Veronique Minard; Nadège Corradini; Guy Leverger; Florent de Vathaire
Journal:  J Clin Oncol       Date:  2009-10-13       Impact factor: 44.544

Review 8.  Side effects of ifosfamide.

Authors:  J Klastersky
Journal:  Oncology       Date:  2003       Impact factor: 2.935

9.  Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group.

Authors:  R Skinner; S J Cotterill; M C Stevens
Journal:  Br J Cancer       Date:  2000-05       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.